Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical held its annual general meeting along with the first class meetings for A and H shareholders, where several key resolutions were passed. These included the re-election and election of directors, the cancellation of the supervisory committee, the retirement of supervisors, and the distribution of a final dividend. The meetings also addressed the closure of the register of members for H shares, with a significant number of shareholders participating in the voting process. This series of resolutions is expected to streamline the company’s governance structure and potentially enhance shareholder value.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, primarily engaged in the pharmaceutical industry. The company focuses on the development, manufacturing, and sale of pharmaceutical products and medical devices, with a significant market presence in China.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.